neuroendocrine tumor

You have access
Identification of Wandering Masses and Tumor Heterogeneity on ⁶⁸Ga-DOTATATE and ¹⁸F-FDG PET/CT in Metastatic Grade II Neuroendocrine Tumor with Increased Somatostatin Receptor Expression After Combined Chemotherapy and PRRT
Parth Baberwal, Rahul Parghane and Sandip Basu

Journal of Nuclear Medicine Technology September 1, 2024, 52 (3) 272-273; DOI: https://doi.org/10.2967/jnmt.123.267286
You have access
Practical Considerations for Implementation of ¹⁷⁷Lu-DOTATATE Neuroendocrine Tumor Treatment Programs
Diane K. Soulek, Molly E. Martin, Nic J. Mastascusa and Stephen A. Graves

Journal of Nuclear Medicine Technology September 1, 2022, 50 (3) 195-202; DOI: https://doi.org/10.2967/jnmt.122.263813
You have access
Poorly Differentiated Neuroendocrine Carcinoma of the Parotid Gland and Moderately Differentiated Hepatic Metastases: A Discordant Histopathology Clarified by Dual-Tracer PET/CT
Priyanka Sharma and Sandip Basu

Journal of Nuclear Medicine Technology March 1, 2021, 49 (1) 86-88; DOI: https://doi.org/10.2967/jnmt.120.251587
You have access
Triple Tracer Positivity in Metastatic Lymph Nodes from Well-Differentiated Neuroendocrine Tumor in MEN-1 Syndrome
Anwin Joseph Kavanal, Sanjay K. Bhadada, Ashwani Sood, Gurjeet Kaur, Amber Parwaiz, Ajay Gulati, Divya Dahiya and Bhagwant Rai Mittal

Journal of Nuclear Medicine Technology September 1, 2020, 48 (3) 287-289; DOI: https://doi.org/10.2967/jnmt.119.237339
You have access
Occurrence of the Redifferentiation-Akin Phenomenon on ⁶⁸Ga-DOTATATE PET/CT After CAPTEM Chemotherapy in Metastatic Neuroendocrine Tumors with Intermediate MIB1 Index: What Could Be the Molecular Explanation?
Priyanka Sharma and Sandip Basu

Journal of Nuclear Medicine Technology September 1, 2020, 48 (3) 290-291; DOI: https://doi.org/10.2967/jnmt.120.241539
You have access
Rare-Site Primary Soft-Tissue Neuroendocrine Tumor with Metastases and Near-Complete Resolution with ¹⁷⁷Lu-DOTATATE: Documenting a Promising Clinical Application of Peptide Receptor Radionuclide Therapy
Aadil Adnan and Sandip Basu

Journal of Nuclear Medicine Technology March 1, 2020, 48 (1) 36-39; DOI: https://doi.org/10.2967/jnmt.119.227058
You have access
An Introduction to Newer PET Diagnostic Agents and Related Therapeutic Radiopharmaceuticals
Ellie Mantel and Jessica Williams

Journal of Nuclear Medicine Technology September 1, 2019, 47 (3) 203-209; DOI: https://doi.org/10.2967/jnmt.118.224022
You have access
Guidance on ¹⁷⁷Lu-DOTATATE Peptide Receptor Radionuclide Therapy from the Experience of a Single Nuclear Medicine Division
Amanda Abbott, Christopher G. Sakellis, Eric Andersen, Yuji Kuzuhara, Lauren Gilbert, Kelly Boyle, Matthew H. Kulke, Jennifer A. Chan, Heather A. Jacene and Annick D. Van den Abbeele

Journal of Nuclear Medicine Technology September 1, 2018, 46 (3) 237-244; DOI: https://doi.org/10.2967/jnmt.118.209148
You have access
Peptide Receptor Radionuclide Therapy with ¹⁷⁷Lu-DOTATATE in Carcinoid Heart Disease: A Contraindication or a Promising Treatment Approach Bettering Chances for Corrective Surgery?
Sudha Ramesh, Shreyas Kudachi and Sandip Basu

Journal of Nuclear Medicine Technology September 1, 2018, 46 (3) 292-294; DOI: https://doi.org/10.2967/jnmt.118.210179
You have access
⁶⁸Ga-DOTATATE PET/CT Can Be an Alternative Imaging Method in Insulinoma Patients
Sadiye Altun Tuzcu, Zafer Pekkolay, Faruk Kılınç and Alpaslan Kemal Tuzcu

Journal of Nuclear Medicine Technology September 1, 2017, 45 (3) 198-200; DOI: https://doi.org/10.2967/jnmt.117.192708

Main menu

User menu

Search

neuroendocrine tumor

Pages